Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension
Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received tentative approval from the United
September 28, 2026